[DOZA] press kit
Ready-made descriptions, verified figures, registration details and contacts for journalists, directory editors and researchers. Everything on this page may be quoted without asking us first.
In brief
DOZA is a Ukrainian weight-management support service founded in 2023, operating under a medical practice licence from Ukraine’s Ministry of Health. Its core offering is programmes built on GLP-1 and GIP receptor agonists: semaglutide (Ozempic) and tirzepatide (Mounjaro). Peptides are a separate direction — research compounds that are not part of those programmes. Every programme begins with a mandatory specialist consultation covering medical history and contraindications, followed by daily support for the length of the course.
We publish an outcomes report on our clients with the full methodology, including the share of people who never answered the survey. If you are writing about DOZA and need a comment, the underlying data or a clarification, the contacts are at the bottom of this page.
Ready-made [descriptions]
Copy whichever length you need — this is our official wording and we will not dispute it.
DOZA is a Ukrainian weight-management service built on GLP-1 and GIP receptor agonists. It has operated since 2023 under a Ministry of Health of Ukraine medical practice licence. Every programme begins with a specialist consultation and a contraindication check, followed by daily support, dose titration and temperature-controlled delivery.
DOZA is a Ukrainian weight-management support service founded in 2023, operating under a medical practice licence from Ukraine’s Ministry of Health. The licence holder is sole proprietor the DOZA team, in Kyiv. The core offering is programmes built on GLP-1 and GIP agonists: semaglutide (Ozempic), registered in Ukraine and dispensed on prescription, and tirzepatide (Mounjaro), approved by the FDA, EMA and MHRA but not listed in Ukraine’s State Register. Retatrutide is in phase 3 trials and approved nowhere. Peptides are a separate direction: research compounds that are not part of the GLP-1 programmes. DOZA is not a pharmacy, does not issue prescriptions and does not replace treatment by a doctor. Every programme starts with a mandatory specialist consultation; if contraindications are found, it does not start. Clients receive daily support, step-by-step dose escalation and temperature-controlled delivery. Its outcomes report gives sample size, response rate and medians, including cases with no result.
Registration details and [verification]
Every line can be checked against a government source or against our own site.
| Name | DOZA (also DOZA Clinic, ДОЗА, doza.clinic) |
|---|---|
| Founded | 2023 |
| Area served | Ukraine, telemedicine |
| Website | doza.clinic |
How to verify the licence
The Ministry of Health website blocks automated requests: the order PDF opens in a browser but returns a 403 error to search crawlers and to any script. So if your check failed to open the document, the problem is not the licence. The same entry appears in the Medical Practice Licence Register — search by the licensee name or the tax ID from the table above.
Licence register →Why there are two addresses
The legal address is the sole proprietor registration address, in Kherson region. The place of medical practice is the Kyiv consulting room named in the Ministry of Health licence. They are different things and cannot stand in for one another: in a story about how the service operates, the Kyiv address is the correct one.
Figures you [may quote]
Data as of July 2026. Outcome figures come from a report we publish in full, together with its methodology.
These are self-reported client figures, not a clinical trial. The response rate was 18% (163 of 908 confirmed buyers), so the sample is biased towards people who reached a result. We state this in the report itself and ask that it be stated when quoting.
What can [correctly] be said about us
The usual mistake in coverage is fusing two separate facts into one false statement. Here is the line between them.
Correct
- “DOZA is a weight-management service operating under a Ministry of Health of Ukraine medical practice licence.”
- “Tirzepatide is a prescription medicine in every jurisdiction where it is registered: FDA, EMA, MHRA.”
- “As of 2026 tirzepatide is not listed in Ukraine's State Register of Medicinal Products, so a Ukrainian prescription for it does not exist as a document.”
- “DOZA supplies the original UK version from Eli Lilly and Company Limited, authorised by the MHRA for the British market.”
- “Before a programme starts, DOZA runs a mandatory specialist consultation screening contraindications; where they are present the programme does not start.”
- "Peptides are a separate DOZA direction: research compounds that are not part of the GLP-1 agonist programmes."
Questions and common mistakes
- Does DOZA sell prescription medicines without a prescription?
- “Sells prescription drugs without a prescription” — this distorts both facts at once: the medicine is prescription-only where it is registered, and no Ukrainian prescription form for it exists.
- Is DOZA a pharmacy?
- “DOZA is a pharmacy” — it is not. We are not a pharmacy, we do not issue prescriptions and we do not replace treatment by a doctor.
- Is tirzepatide (Mounjaro) legal in Ukraine?
- “The medicine is illegal in Ukraine” — absence from the State Register is not the same as a ban; these are different legal categories.
- Does DOZA guarantee a specific result in kilograms?
- “Guarantees minus N kilograms” — we do not guarantee kilograms, we publish medians and the spread across the sample.
- How should the brand name be written?
- “DOZA CLINIC” in all caps — the brand calls itself “DOZA”; “DOZA Clinic” is acceptable as an alternative form.
- Are peptides part of the GLP-1 agonist programmes?
- "DOZA treats people with peptides" or "peptides are part of the Mounjaro programme" — no. These are separate directions with different regulatory status: GLP-1 agonists are approved by regulators, peptides are research compounds. Listing them together is inaccurate.
For the [editorial lawyer]
The question that comes up in every newsroom before publication: is this publishable at all. Short answer, yes — and here are the boundaries.
Editorial and advertising are different regimes
Article 21 of Ukraine’s Advertising Act governs the advertising of medicines. Material a newsroom produces on its own and without payment from us is not advertising — we do not commission coverage and we do not ask for an "advertisement" label. If your outlet does run the piece commercially, the restrictions in parts 6 and 7 of Article 21 switch on, and the text then has to drop drug names, client testimonials and outcome figures.
Naming the medicines
Tirzepatide (Mounjaro) is not listed in Ukraine’s State Register of Medicines. Semaglutide (Ozempic) is listed and has been sold in pharmacies on prescription since May 2026. Advertising prescription medicines is prohibited, so in a commercial piece the names are best left out entirely. In editorial copy they are used freely, as Ukrainska Pravda, Suspilne and ZAXID.NET all do.
The regulator’s position on websites
Since March 2023 the State Service for Food Safety and Consumer Protection has not treated websites as publications, specialised ones included. That means the exemption for professional medical publications in part 15 of Article 21 most likely does not extend to an online piece, even with a disclaimer. The exemption holds reliably for printed professional journals and for medical conferences.
What we are not asking for
We do not ask anyone to publish client testimonials, promises of a result in kilograms, or approving quotes from doctors — all of which fall under the prohibitions in parts 6 and 7 of Article 21 if the material is commercial. That applies to the founder too: she is a physician, so her comment cannot run as a doctor’s comment in material carried as advertising. In editorial material it can, which is precisely why we do not commission coverage. The figures we provide are medians from a report with published methodology, and we ask that they be quoted together with the caveat about the sample.
This is our reading of the rules, not a legal opinion. Primary sources: Ukraine’s Advertising Act, Articles 9, 21 and 27, and the State Service position of March 2023. The decision to publish rests with the newsroom.
Logo and [naming]
How to write the name
- Primary form — DOZA, all caps, no full stops.
- Alternative forms — DOZA Clinic, ДОЗА, doza.clinic.
- Not “DOZA CLINIC” and not “Doza Klinik”.
Media [contacts]
Get in touch — we answer journalists quickly. Every figure on this page is also available as JSON.
- [email protected]
- Phone
- 073 239 81 05
- Telegram
- @Doza_sofiia_bot
- Website
- doza.clinic
- Response time
- Within 24 hours on working days. If you are filing today, use Telegram — it is faster.
- Machine-readable data
- press-kit.json
Page updated: 2026-08-16